stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) EPS (diluted)
PTC Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was $7.78, compared with −$4.73 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.40. Over the past ten years it has ranged from −$8.37 (fiscal 2023) to $7.78 (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 259th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $7.78 | — |
| FY2024 | −$4.73 | — |
| FY2023 | −$8.37 | — |
| FY2022 | −$7.79 | — |
| FY2021 | −$7.43 | — |
| FY2020 | −$6.64 | — |
| FY2019 | −$4.27 | — |
| FY2018 | −$2.75 | — |
| FY2017 | −$2.02 | — |
| FY2016 | −$4.17 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.62 | — |
| Jun 2026 | $0.92 | — |
| Mar 2026 | −$0.03 | — |
| Dec 2025 | −$1.67 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| PTCT PTC Therapeutics, Inc. | −$1.40 |
| COGT Cogent Biosciences, Inc. compare | −$2.16 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| SRRK Scholar Rock Holding Corporation compare | −$3.32 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PTCT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement